Pharmacokinetic and pharmacodynamic target attainment of ceftazidime in adult patients on general wards with different degrees of renal function: a prospective observational cohort study.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON25634

Enrollment

Registered

2019-07-03

Start date

2019-07-03

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bacterial infections

Interventions

Three venapunctures

Eligibility

Inclusion criteria

Inclusion criteria: Receiving ceftazidime therapy intravenous (iv) as part of standard care Age = 18 years Admitted to a general ward of Amsterdam UMC - location AMC Informed consent is obtained

Exclusion criteria

Exclusion criteria: Renal replacement therapy during treatment with ceftazidime Patients admitted to the intensive care unit (ICU) Severely burned patients, defined as a burned surface = 10% Patients with cystic fibrosis Informed consent is not obtained

Design outcomes

Primary

Measure	Time frame
PK-PD target attainment of 50%T>MIC during the first 24 hours of therapy	—

Secondary

Measure	Time frame
50%T>MIC after 24-48 hours of therapy PK-PD target attainment of 100%T>MIC during the first 24 hours of therapy To compare ceftazidime exposure at 24 hours and 24-48 hours after start of treatment between three different renal function groups in terms of AUC and Cmin Clinical outcome	—

Contacts

Public ContactSuzanne L. de Vroom

Amsterdam UMC, location Academic Medical Centre (AMC), University of Amsterdam

s.l.devroom@amc.uva.nl0031 (0)6 29189028

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)